7 papers reviewed
Recurrent Thrush, UTI & Other Common Infections
2022 · review · 1 of 7
Management of recurrent vulvovaginal candidosis: narrative review of the literature and European expert panel opinion
— · Frontiers in Cellular and Infection Microbiology
Recurrent vulvovaginal candidiasis is defined as three or more symptomatic episodes in a year and affects roughly 5-8% of reproductive-age women. Management priorities: remove reversible risk factors first (glycaemic control, antibiotic stewardship, immunosuppression, contraceptive method), then symptomatic relief, pathogen clearance and relapse prevention.
Read the paper ↗2004 · RCT · 2 of 7
Maintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis
Sobel JD et al. · New England Journal of Medicine
Foundational trial establishing weekly suppressive fluconazole for RVVC — effective during treatment, with relapse common after discontinuation. Frames maintenance therapy as suppression rather than cure, which is why underlying drivers matter.
Read the paper ↗2025 · retrospective cohort · 3 of 7
Recurrent Vulvovaginal Candidiasis Caused by Fluconazole-Resistant Candida albicans: A Retrospective Study
— · Infection and Drug Resistance / PMC
Azole overexposure drives fluconazole-resistant C. albicans; risk of mycologic failure rose with cumulative fluconazole use, with 16 of 25 women having had low-dose weekly maintenance. Non-albicans species — often intrinsically azole-resistant — are rising in prevalence.
Read the paper ↗2024 · review · 4 of 7
Fluconazole-Resistant Vulvovaginal Candidosis: An Update on Current Management
— · Pharmaceutics
Reviews second-line options where azoles fail, including intravaginal boric acid for non-albicans species. Reinforces that species identification changes management and that empiric repeat azole dosing is a common failure mode.
Read the paper ↗2024 · RCT · 5 of 7
d-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women: A Randomized Clinical Trial
Hayward G et al. · JAMA Internal Medicine
Definitive negative trial: in 598 women with recurrent UTI, 51.0% on daily D-mannose had a medically attended UTI over 6 months versus 55.7% on placebo — no meaningful difference. Authors conclude D-mannose should not be recommended for prevention in primary care. A widely sold supplement that did not survive a properly powered trial.
Read the paper ↗2025 · systematic review / meta-analysis · 6 of 7
D-Mannose for prevention of recurrent urinary tract infection in adult women: an updated systematic review and meta-analysis of randomized controlled trials
Murali Krishna M et al. · Journal of Infection Prevention
Updated pooled analysis incorporating the 2024 trial, providing the current best estimate of D-mannose efficacy and confirming the earlier positive signal did not replicate in larger, better-controlled studies.
Read the paper ↗2023 · RCT · 7 of 7
d-Mannose for Recurrent Urinary Tract Infection Prevention in Postmenopausal Women Using Vaginal Estrogen: A Randomized Controlled Trial
— · Urogynecology
Found no significant additional benefit of D-mannose beyond vaginal estrogen therapy alone in postmenopausal women, reinforcing vaginal estrogen — not supplements — as the effective intervention in that population.
Read the paper ↗A paper's presence documents the evidence reviewed; it does not mean Filia endorses every intervention or conclusion.